Injectable and In Situ Phospholipid-Based Phase Separation Gel for Sustained Delivery of Altrenogest

Dongbo Li, Awn Abbas, Nanxin Li, Chao Li, Xiaoyang Ai, Lian Chen, Dongmei Dai, Gang Shu, Juchun Lin, Wei Zhang, Guangneng Peng, Haohuan Li, Funeng Xu, Hualin FuGels 2024 · DOI

TL;DR

This paper introduces a novel injectable phospholipid-based gel for sustained delivery of altrenogest, a hormone crucial for managing sow reproduction. This new formulation significantly reduces the frequency of administration compared to current oral solutions, offering a more efficient and potentially more effective method for swine production.

What Problem Does This Paper Address?

Altrenogest is a vital synthetic hormone used in intensive swine farming to synchronize estrus and ovulation in sows, thereby improving breeding efficiency and farm economics. However, the current standard treatment involves daily oral administration of altrenogest solutions for over two weeks. This frequent dosing regime is labor-intensive and costly for farms. The existing challenge is to develop a drug delivery system that can provide sustained release of altrenogest, reducing the need for daily administration while maintaining or enhancing therapeutic efficacy.

Methods

The researchers developed an injectable, in-situ forming phospholipid-based gel. The core of their approach involves a phase separation mechanism: the gel, initially a low-viscosity solution, transitions into a high-viscosity gel upon injection into the body. This transition is triggered by the diffusion of ethanol (a solvent in the formulation) into the surrounding aqueous environment and the subsequent precipitation of phospholipids.

Key characterization techniques included:

  • Viscosity measurements: To assess the gel's fluidity before injection and its solidification after contact with physiological saline.
  • In vitro release studies: To evaluate the rate and duration of altrenogest release from the gel under different conditions (PBS, PBS with varying ethanol concentrations).
  • Storage stability tests: To determine how altrenogest content and gel viscosity are affected by storage conditions (temperature, atmosphere).
  • In vivo pharmacokinetic studies: To compare the absorption, distribution, metabolism, and excretion of altrenogest from the gel formulation versus the oral solution in rats.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from in vitro and in vivo studies using the developed gel formulation and altrenogest solutions.

Key Insights and Ideas

  • In-situ gelation for sustained release: The phospholipid-based gel's ability to transition from a low-viscosity liquid to a high-viscosity solid in situ is the cornerstone of its sustained release capability. This avoids the need for pre-formed gels and allows for easy injection.
  • Phospholipid precipitation as a drug reservoir: The precipitation of phospholipids upon contact with aqueous environments creates a matrix that entraps altrenogest, acting as a slow-release reservoir. This mechanism is key to achieving prolonged drug delivery.
  • Ethanol as a trigger and solubilizer: Ethanol plays a dual role: it keeps the phospholipids and altrenogest dissolved in the initial solution and its diffusion out of the gel triggers the phase transition. Its presence in release media also influences the rate of drug release.
  • Nitrogen protection for stability: The study highlights the importance of an inert atmosphere (nitrogen) for maintaining the altrenogest content and gel stability, suggesting that oxidation is a key degradation pathway.

Key Results

  • Viscosity transformation: The gel exhibited a dramatic viscosity increase from ~100 cP before phase transition to over 1,000,000 cP after contact with physiological saline, ensuring it forms a stable implant.
  • Sustained in vitro release: The altrenogest gel demonstrated continuous release of the drug for over two weeks in PBS medium.
  • Enhanced in vivo bioavailability: The area under the curve (AUC) for the altrenogest gel was nearly double that of the oral solution, indicating improved overall drug exposure.
  • Prolonged half-life: The mean residence time (MRT) and half-life (t1/2) of altrenogest were significantly extended with the gel formulation (MRT: 40.92 ± 7.21 h, t1/2: 80.03 ± 20.79 h) compared to the oral solution.
  • Storage stability: Altrenogest content remained stable for 20 days at 4°C and 25°C when stored under a nitrogen atmosphere, while unsealed samples showed significant degradation.

Limitations and Future Work

  • Animal model: The pharmacokinetic studies were conducted in rats, and the authors acknowledge that the sustained-release effect in clinical pigs might differ due to dosage and physiological variations.
  • Clinical validation: Pharmacokinetic and pharmacodynamic studies have not yet been conducted in sows.
  • Safety and irritation: The safety and potential irritation of the injectable gel in sows need to be evaluated.
  • Future directions: The authors propose further investigation into the drug-release and sustained-release mechanisms, aiming to develop this into a new veterinary drug preparation that can fill the current market gap for long-term altrenogest delivery. They also suggest evaluating its potential to reduce labor costs and increase breeding efficiency.

Summary updated

Abstract

Altrenogest is a key regulatory hormone for intensive and batch management of reserve sows in breeding farms. As a synthetic hormone, altrenogest could make ovaries stay at the initial stage of follicles and inhibit estrus and ovulation in animals. However, the currently used oral altrenogest solution needs to be administered continuously every day for more than two weeks in clinical practice. In this study we developed a phospholipid-based injectable gel carrying altrenogest to decrease the number of administrations, sustain release of the drug, and enhance therapeutic efficacy for clinical use. The altrenogest gel had a viscosity of 100 cP before phase transition and over 1,000,000 cP after phase transition. In vitro, altrenogest can be continuously released from gel for over two weeks. The pharmacokinetic results showed that the AUC <sub>(0-∞)</sub> of the altrenogest gel was almost double that of the altrenogest solution. The MRT <sub>(0-∞)</sub> was 40.92 ± 7.21 h and the t<sub>1/2</sub> of the altrenogest gel was 80.03 ± 20.79 h. The altrenogest gel demonstrated excellent fluidity, ease of injectability, high drug-loading capacity, and appropriate sustained-release characteristics both in vitro and in vivo, making it a potential drug delivery system for swine production.
BibTeX
@inproceedings{li2024injectable,
  author = {Dongbo Li and Awn Abbas and Nanxin Li and Chao Li and Xiaoyang Ai and Lian Chen and Dongmei Dai and Gang Shu and Juchun Lin and Wei Zhang and Guangneng Peng and Haohuan Li and Funeng Xu and Hualin Fu},
  title = {{Injectable and In Situ Phospholipid-Based Phase Separation Gel for Sustained Delivery of Altrenogest}},
  booktitle = {Gels},
  year = {2024},
  doi = {10.3390/gels10120847},
}
Figure